[A16-63] Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 16.03.2017
Project no.:
A16-63
Commission:
Commission awarded on 29.09.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-19 | Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-57 | Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-122 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-160 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-162 | Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-03-16 A G-BA decision was published.